We are live on ! Find out more
DSGN icon

Design Therapeutics
DSGN

93 hedge funds and large institutions have $124M invested in Design Therapeutics in 2024 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 21 increasing their positions, 37 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

45% more capital invested

Capital invested by funds: $85.5M → $124M (+$38.4M)

36% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 14

6% more funds holding

Funds holding: 88 → 93 (+5)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

3.21% less ownership

Funds ownership: 57.61% → 54.39% (-3.2%)

43% less repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 37

78% less call options, than puts

Call options by funds: $4K | Put options by funds: $18K

Holders
93
Holders Change
+5
Holders Change %
+5.68%
% of All Funds
1.34%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
19
Increased
21
Reduced
37
Closed
14
Calls
$4K
Puts
$18K
Net Calls
-$14K
Net Calls Change
+$68K

Top Buyers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$1.59M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$771K
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$595K
4
Wellington Management Group
Wellington Management Group
Massachusetts
+$572K
5
BBA
Baker Bros. Advisors
New York
+$433K

Top Sellers

1
Citadel Advisors
Citadel Advisors
Florida
-$2.56M
2
Morgan Stanley
Morgan Stanley
New York
-$1.63M
3
Goldman Sachs
Goldman Sachs
New York
-$1.38M
4
PM
Prosight Management
Texas
-$742K
5
CS
Candriam SCA
Luxembourg
-$596K
Name Holding Trade Value Shares
Change 		Change in
Stake
SOCM
1
SR One Capital Management
Pennsylvania
$26.3M – – –
LGM
2
Logos Global Management
California
$20.3M – – –
BlackRock
3
BlackRock
New York
$9.16M -$283K -106,051 -4%
BBA
4
Baker Bros. Advisors
New York
$6.7M +$433K +162,120 +11%
TCM
5
Tang Capital Management
California
$5.97M +$801 +300 +0%
Vanguard Group
6
Vanguard Group
Pennsylvania
$5.18M +$771K +288,803 +29%
AC
7
Almitas Capital
California
$4.14M – – –
BCM
8
BML Capital Management
Indiana
$3.54M -$401K -150,000 -15%
Citadel Advisors
9
Citadel Advisors
Florida
$3.53M -$2.56M -957,477 -52%
State Street
10
State Street
Massachusetts
$2.82M +$10K +3,762 +0.5%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$2.76M +$56.5K +21,154 +3%
Point72 Asset Management
12
Point72 Asset Management
Connecticut
$2.39M +$1.59M +593,516 New
Goldman Sachs
13
Goldman Sachs
New York
$2.04M -$1.38M -517,467 -51%
Jacobs Levy Equity Management
14
Jacobs Levy Equity Management
New Jersey
$2.02M -$126K -47,098 -9%
Millennium Management
15
Millennium Management
New York
$1.95M +$172K +64,405 +15%
Morgan Stanley
16
Morgan Stanley
New York
$1.93M -$1.63M -608,870 -56%
Renaissance Technologies
17
Renaissance Technologies
New York
$1.83M -$522K -195,400 -30%
D.E. Shaw & Co
18
D.E. Shaw & Co
New York
$1.8M +$415K +155,562 +54%
Two Sigma Investments
19
Two Sigma Investments
New York
$1.7M -$16.4K -6,136 -1%
Two Sigma Advisers
20
Two Sigma Advisers
New York
$1.63M -$483K -181,000 -31%
Acadian Asset Management
21
Acadian Asset Management
Massachusetts
$1.63M +$595K +222,805 +123%
Northern Trust
22
Northern Trust
Illinois
$1.44M -$41.8K -15,643 -4%
Assenagon Asset Management
23
Assenagon Asset Management
Luxembourg
$1.4M +$274K +102,567 +42%
PGCM
24
Prescott Group Capital Management
Oklahoma
$1.38M – – –
GCP
25
GSA Capital Partners
United Kingdom
$872K +$385K +144,055 +199%
1
2 3 4 5

DSGN Hedge Fund Activity: Q1 2024 in Review

93 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Design Therapeutics (DSGN) for Q1 2024, worth a combined $124M — up 45% from $85.5M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new DSGN positions and 14 closed out — a net gain of 5 holders — while 21 added to existing stakes and 37 trimmed.

The largest buyer was Point72 Asset Management, opening a new position worth an estimated $1.59M. The largest seller was Citadel Advisors, cutting an estimated $2.56M.

  • 93 institutional investors held Design Therapeutics (DSGN) as of Q1 2024, up from 88 in Q4 2023.
  • Funds reported $124M of Design Therapeutics stock for Q1 2024, up 45% quarter-over-quarter.
  • 19 funds opened new Design Therapeutics positions in Q1 2024 and 14 closed out, a net change of +5 holders.
  • The largest Design Therapeutics buyer in Q1 2024 was Point72 Asset Management, an estimated $1.59M added.
  • The largest Design Therapeutics seller in Q1 2024 was Citadel Advisors, an estimated $2.56M sold.

Based on aggregated 13F filings for Q1 2024.